(Reuters) – Eli Lilly beat Wall Street’s revenue estimates for the third quarter on Thursday, lifted by strong demand for its diabetes drug Mounjaro that brought in over a billion dollars in sales. The U.S. drugmaker reported revenue of about $9.50 billion, compared with analysts’ average expectation of $8.95 billion, according to LSEG data.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli)
